CA2776545A1 - Apparatus and method to characterize blood and red blood cells via erythrocyte membrane fragility quantification - Google Patents
Apparatus and method to characterize blood and red blood cells via erythrocyte membrane fragility quantification Download PDFInfo
- Publication number
- CA2776545A1 CA2776545A1 CA2776545A CA2776545A CA2776545A1 CA 2776545 A1 CA2776545 A1 CA 2776545A1 CA 2776545 A CA2776545 A CA 2776545A CA 2776545 A CA2776545 A CA 2776545A CA 2776545 A1 CA2776545 A1 CA 2776545A1
- Authority
- CA
- Canada
- Prior art keywords
- rbc
- fragility
- blood
- hemolysis
- unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 212
- 239000008280 blood Substances 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 43
- 210000003617 erythrocyte membrane Anatomy 0.000 title claims description 8
- 210000000601 blood cell Anatomy 0.000 title description 3
- 238000011002 quantification Methods 0.000 title description 3
- 210000004369 blood Anatomy 0.000 claims abstract description 61
- 206010018910 Haemolysis Diseases 0.000 claims abstract description 58
- 230000008588 hemolysis Effects 0.000 claims abstract description 58
- 230000003287 optical effect Effects 0.000 claims abstract description 36
- 238000004458 analytical method Methods 0.000 claims abstract description 27
- 230000008569 process Effects 0.000 claims abstract description 8
- 238000003860 storage Methods 0.000 claims description 32
- 239000012528 membrane Substances 0.000 claims description 25
- 108010054147 Hemoglobins Proteins 0.000 claims description 24
- 102000001554 Hemoglobins Human genes 0.000 claims description 24
- 238000001727 in vivo Methods 0.000 claims description 19
- 230000008859 change Effects 0.000 claims description 18
- 238000012545 processing Methods 0.000 claims description 8
- 238000011156 evaluation Methods 0.000 claims description 5
- 230000031700 light absorption Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 230000000877 morphologic effect Effects 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 45
- 230000015556 catabolic process Effects 0.000 abstract description 31
- 238000006731 degradation reaction Methods 0.000 abstract description 31
- 230000035899 viability Effects 0.000 abstract description 24
- 238000009826 distribution Methods 0.000 abstract description 18
- 238000003908 quality control method Methods 0.000 abstract description 6
- 238000013439 planning Methods 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 238000009825 accumulation Methods 0.000 abstract description 3
- 238000010205 computational analysis Methods 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000035882 stress Effects 0.000 description 98
- 239000000523 sample Substances 0.000 description 58
- 210000004027 cell Anatomy 0.000 description 38
- 230000009089 cytolysis Effects 0.000 description 27
- 230000004083 survival effect Effects 0.000 description 16
- 230000003466 anti-cipated effect Effects 0.000 description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 238000012512 characterization method Methods 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 208000014674 injury Diseases 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000008733 trauma Effects 0.000 description 8
- 239000010836 blood and blood product Substances 0.000 description 7
- 229940125691 blood product Drugs 0.000 description 7
- 238000012384 transportation and delivery Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 208000035404 Autolysis Diseases 0.000 description 5
- 206010057248 Cell death Diseases 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000028043 self proteolysis Effects 0.000 description 5
- 208000007056 sickle cell anemia Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- 230000036770 blood supply Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 238000006213 oxygenation reaction Methods 0.000 description 4
- 230000000287 tissue oxygenation Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010183 spectrum analysis Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010016803 Fluid overload Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000001272 nitrous oxide Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 1
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710169609 Hemoglobin-3 Proteins 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 206010071090 Transfusion related complication Diseases 0.000 description 1
- 208000007587 Transfusion-Related Acute Lung Injury Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- -1 carboxy- Chemical class 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000012576 optical tweezer Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037918 transfusion-transmitted disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/726—Devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14614509P | 2009-01-21 | 2009-01-21 | |
| US61/146,145 | 2009-01-21 | ||
| US12/690,916 US8026102B2 (en) | 2009-01-21 | 2010-01-20 | Apparatus and method to characterize blood and red blood cells via erythrocyte membrane fragility quantification |
| US12/690,916 | 2010-01-20 | ||
| PCT/US2010/021559 WO2010090848A2 (en) | 2009-01-21 | 2010-01-21 | Apparatus and method to characterize blood and red blood cells via erythrocyte membrane fragility quantification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2776545A1 true CA2776545A1 (en) | 2010-08-12 |
Family
ID=42337264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2776545A Abandoned CA2776545A1 (en) | 2009-01-21 | 2010-01-21 | Apparatus and method to characterize blood and red blood cells via erythrocyte membrane fragility quantification |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US8026102B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2382464A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5620407B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2776545A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2010090848A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8980568B2 (en) | 2001-10-11 | 2015-03-17 | Aviva Biosciences Corporation | Methods and compositions for detecting non-hematopoietic cells from a blood sample |
| US8986944B2 (en) * | 2001-10-11 | 2015-03-24 | Aviva Biosciences Corporation | Methods and compositions for separating rare cells from fluid samples |
| CA2657621A1 (en) | 2006-07-14 | 2008-01-17 | Aviva Biosciences Corporation | Methods and compositions for detecting rare cells from a biological sample |
| US20120010919A1 (en) * | 2009-03-09 | 2012-01-12 | Abhilasha Aswal | New vistas in inventory optimization under uncertainty |
| KR20150119118A (ko) * | 2013-02-14 | 2015-10-23 | 메타노믹스 헬스 게엠베하 | 생물학적 샘플의 품질 평가 수단 및 방법 |
| WO2014137499A1 (en) * | 2013-03-06 | 2014-09-12 | Blaze Medical Devices, LLC | Bead mill and method of use |
| US10900954B2 (en) * | 2015-04-14 | 2021-01-26 | Blaze Medical Devices, Inc. | Method and system for inducing controlled and varied fluid stresses by bead oscillation |
| CA3022276C (en) | 2016-05-11 | 2024-01-02 | Nova Biomedical Corporation | Whole blood so2 sensor |
| WO2020219825A1 (en) | 2019-04-24 | 2020-10-29 | Cornell University | Systems, compositions, and methods for evaluating biomechanical properties of cells |
| WO2025212164A1 (en) | 2024-04-05 | 2025-10-09 | Massachusetts Institute Of Technology | Apparatus for high throughput assessment of cell properties, fragility or deformability |
| WO2025255145A1 (en) * | 2024-06-05 | 2025-12-11 | Fenwal, Inc. | System and method for determining red blood cell and buffy coat platelet quality based on plasma characterization |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4040742A (en) * | 1976-08-09 | 1977-08-09 | The United States Of America As Represented By The Secretary Of The Department Of Health, Education And Welfare | Capillary flow method and apparatus for determination of cell osmotic fragility |
| US4178152A (en) * | 1977-02-24 | 1979-12-11 | Sanki Engineering Ltd. | Cell fragility testing method and appliance therefor |
| US4402216A (en) * | 1981-08-31 | 1983-09-06 | Nuclepore Corporation | Erythrocyte deformability monitor |
| US4491012A (en) * | 1982-10-04 | 1985-01-01 | Nuclepore Corp. | Method for measuring erythrocyte deformability |
| DE3522186A1 (de) * | 1985-06-21 | 1987-01-02 | Hoechst Ag | Messeinrichtung zum messen des verformungsvermoegens von roten blutkoerperchen |
| FR2825637B1 (fr) * | 2001-06-12 | 2003-09-12 | Biolog | Procede de determination et de suivi du vieillissement des poches de sang dans les etablissements de transfusion sanguine et les etablissements de soins |
| JP2004138561A (ja) * | 2002-10-18 | 2004-05-13 | Setsuo Takatani | 赤血球蓄積負荷状態測定方法および装置 |
| US7517453B2 (en) * | 2003-03-01 | 2009-04-14 | The Trustees Of Boston University | Microvascular network device |
| US7629165B2 (en) * | 2004-01-22 | 2009-12-08 | Qualigen, Inc | Diagnostic device and method |
| EP1864112B1 (en) * | 2005-03-25 | 2015-05-06 | Massachusetts Institute of Technology | Device and method for hilbert phase imaging |
| US7790464B2 (en) * | 2006-05-04 | 2010-09-07 | Blaze Medical Devices, LLC | Blood hemolysis analyzer |
-
2010
- 2010-01-20 US US12/690,916 patent/US8026102B2/en active Active
- 2010-01-21 WO PCT/US2010/021559 patent/WO2010090848A2/en not_active Ceased
- 2010-01-21 EP EP10738938A patent/EP2382464A4/en not_active Withdrawn
- 2010-01-21 JP JP2011546447A patent/JP5620407B2/ja not_active Expired - Fee Related
- 2010-01-21 CA CA2776545A patent/CA2776545A1/en not_active Abandoned
-
2011
- 2011-08-05 US US13/204,372 patent/US8268244B2/en active Active
- 2011-08-05 US US13/204,393 patent/US8263408B2/en active Active
-
2012
- 2012-03-06 US US13/412,691 patent/US20120178121A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8268244B2 (en) | 2012-09-18 |
| EP2382464A2 (en) | 2011-11-02 |
| US20110300573A1 (en) | 2011-12-08 |
| US8263408B2 (en) | 2012-09-11 |
| JP5620407B2 (ja) | 2014-11-05 |
| US8026102B2 (en) | 2011-09-27 |
| WO2010090848A3 (en) | 2010-10-28 |
| WO2010090848A2 (en) | 2010-08-12 |
| US20100184120A1 (en) | 2010-07-22 |
| JP2012515898A (ja) | 2012-07-12 |
| US20120178121A1 (en) | 2012-07-12 |
| US20110287530A1 (en) | 2011-11-24 |
| EP2382464A4 (en) | 2012-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8026102B2 (en) | Apparatus and method to characterize blood and red blood cells via erythrocyte membrane fragility quantification | |
| Bain et al. | Dacie and Lewis practical haematology: expert consult: online and print | |
| Kayiran et al. | Significant differences between capillary and venous complete blood counts in the neonatal period | |
| Piva et al. | Automated reticulocyte counting: state of the art and clinical applications in the evaluation of erythropoiesis. | |
| Kim et al. | Advances in the measurement of red blood cell deformability: A brief review | |
| US8472693B2 (en) | Method for determining at least one hemoglobin related parameter of a whole blood sample | |
| Kur et al. | Evaluation of the HemoCue WBC DIFF in leukopenic patient samples | |
| Grisendi et al. | Detection of microparticles from human red blood cells by multiparametric flow cytometry | |
| KR101885964B1 (ko) | 적혈구의 광 특성을 이용한 당화혈색소 농도 측정 방법 및 장치 | |
| JP2011515682A (ja) | 赤血球中に含まれるヘモグロビンの固有色素を利用して血液試料の赤血球指数を決定するための方法及び装置 | |
| Lecompte et al. | Novel parameters in blood cell counters | |
| Atkins et al. | Using Raman spectroscopy to assess hemoglobin oxygenation in red blood cell concentrate: an objective proxy for morphological index to gauge the quality of stored blood? | |
| US20220293210A1 (en) | Single-cell modeling of clinical data to determine red blood cell regulation | |
| Freise et al. | The effect of anticoagulant, storage temperature and dilution on cord blood hematology parameters over time | |
| Schaefer et al. | Retrospective study of reticulocyte indices as indicators of iron-restricted erythropoiesis in dogs with immune-mediated hemolytic anemia | |
| Spielmann et al. | Accuracy and precision of hemoglobin point‐of‐care testing during major pediatric surgery | |
| Dybas et al. | Label-free testing strategy to evaluate packed red blood cell quality before transfusion to leukemia patients | |
| Can et al. | Estimation of free hemoglobin concentrations in blood bags by diffuse reflectance spectroscopy | |
| US20110318773A1 (en) | Method to use ektacytometry to improve stored red blood cell or whole blood product utilization | |
| Aliviameita et al. | Optimization of Whole Blood Specimen Handling for Complete Blood Count (CBC) Results and Blood Cell Morphology | |
| Lippi et al. | What do hemolyzed whole-blood specimens look like? Analysis with a CellaVision DM96 automated image analysis system | |
| US20140017718A1 (en) | Erythrocyte mechanical fragility test | |
| WO2023242387A1 (en) | Automated fluorescence-based quantification of pocked red cells | |
| Heller et al. | Comparison between the Mission Plus device and gold standard methods for measuring hemoglobin concentrations and packed cell volumes in cattle | |
| Angkoso et al. | The Comparison of Hemoglobin and Leukocytes Examination Between Whole Blood and Pre-Diluted Modes on Hematology Analyzer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150121 |
|
| FZDE | Discontinued |
Effective date: 20170123 |